1
|
Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc 2006; 81:1290-302. [PMID: 17036554 DOI: 10.4065/81.10.1290] [Citation(s) in RCA: 152] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE To perform a meta-analysis of case-control studies that addressed whether prior oral contraceptive (OC) use is associated with premenopausal breast cancer. METHODS We searched the MEDLINE and PubMed databases and bibliography reviews to identify case-control studies of OCs and premenopausal breast cancer published in or after 1980. Search terms used included breast neoplasms, oral contraceptives, contraceptive agents, and case-control studies. Studies reported in all languages were included. Thirty-four studies were identified that met inclusion criteria. Two reviewers extracted data from original research articles or additional data provided by study authors. We used the DerSimonian-Laird method to compute pooled odds ratios (ORs) and confidence intervals (CIs) and the Mantel-Haenszel test to assess association between OC use and cancer. RESULTS Use of OCs was associated with an increased risk of premenopausal breast cancer in general (OR, 1.19; 95% CI, 1.09-1.29) and across various patterns of OC use. Among studies that provided data on nulliparous and parous women separately, OC use was associated with breast cancer risk in both parous (OR, 1.29; 95% CI, 1.20-1.40) and nulliparous (OR, 1.24; 95% CI, 0.92-1.67) women. Longer duration of use did not substantially alter risk in nulliparous women (OR, 1.29; 95% CI, 0.85-1.96). Among parous women, the association was stronger when OCs were used before first full-term pregnancy (FFTP) (OR, 1.44; 95% CI, 1.28-1.62) than after FFTP (OR, 1.15; 95% CI, 1.06-1.26). The association between OC use and breast cancer risk was greatest for parous women who used OCs 4 or more years before FFTP (OR, 1.52; 95% CI, 1.26-1.82). CONCLUSION Use of OCs is associated with an increased risk of premenopausal breast cancer, especially with use before FFTP in parous women.
Collapse
Affiliation(s)
- Chris Kahlenborn
- Department of Internal Medicine, Altoona Hospital, Altoona, PA, USA.
| | | | | | | |
Collapse
|
2
|
Abstract
With the rates of unintended pregnancies in teenagers remaining high, it is crucial to present adolescents with all of the contraceptive options available to them. While barrier methods, for example, male condoms, are easily accessible and do not have adverse effects, their use must be consistent and correct with each act of intercourse. Hormonal contraception affords much better efficacy in preventing pregnancy when used with full compliance. Oral contraceptives are a popular method of contraception among adolescents and offer many non-contraceptive benefits along with the prevention of pregnancy. They have very few significant adverse effects, which are outweighed by the significant morbidity associated with teenage pregnancies, and can be used by most adolescent females. However, their minor bothersome effects do contribute to the high discontinuation rates seen. In addition, many girls find it difficult to remember to take a pill every day, leading to higher failure rates in teenagers than in adult women. The advent of long-acting, progestogen (progestin)-only methods, such as injectables and implantables, has been generally accepted by adolescents and these methods have proven to be more efficacious by avoiding the need for daily compliance. However, progestogen-only methods cause irregular bleeding and amenorrhea, which is not acceptable to many teenagers. In addition, the most widely used implant was taken off the market a few years ago and newer forms are not yet widely accessible. Other novel methods are currently available, including the transdermal patch and the vaginal ring. Both are combinations of estrogen and progestogen and have similar efficacy and adverse effect profiles to oral contraceptives. Their use may be associated with greater compliance by adolescents because they also do not require adherence to a daily regimen. However, there may be some drawbacks with these newer methods, for example, visibility of the patch and difficulty with insertion of the vaginal ring. When regular contraceptive modalities fail, emergency contraception is available. Choices include combination oral contraceptives, progestogen-only pills, mifepristone, or placement of a copper-releasing intrauterine device. These methods can be very useful for preventing pregnancy in adolescents as long as adolescents are aware of their existence and have easy access to them.
Collapse
Affiliation(s)
- Rollyn M Ornstein
- Division of Adolescent Medicine, Schneider Children's Hospital, North Shore-Long Island Jewish Health System, New Hyde Park, New York 11040, USA.
| | | |
Collapse
|
3
|
|
4
|
Lee CY, Ko IS, Kim HS, Lee WH, Chang SB, Min JS, Ham OK, Han JH. Development and validation study of the breast cancer risk appraisal for Korean women. Nurs Health Sci 2004; 6:201-7. [PMID: 15291768 DOI: 10.1111/j.1442-2018.2004.00193.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The purpose of the present study was to develop and validate breast cancer risk factors, which can be used to identify women who are at a high risk of developing breast cancer. Fourteen risk factors for breast cancer were identified from extensive literature reviews and in consultation with a panel of experts. A case-control study was conducted, which aimed to validate these 14 risk factors. Cases were selected from four university hospitals in Korea and controls were selected from health screening centers in Korea. Interviews were used to obtain exposure history of each participant to the 14 risk factors. Group differences between the cases and controls were analyzed using a chi-squared test and a logistic regression method. Among the 14 risk factors, six were identified as significant: meat consumption more than once a week (odds ratio [OR] = 1.56, confidence interval [CI] = 1.32-1.85), breast disease experience (OR = 3.08, CI = 1.49-6.37), less than two children (OR = 1.61, CI = 1.09-2.35), family history of breast cancer (OR = 8.99, CI = 3.89-20.76), and no breast-feeding experience (OR = 3.08, CI = 1.41-3.85). Based on the OR, the risk scores were calculated by the absolute size of the OR having a total of 100 points.
Collapse
Affiliation(s)
- Chung Yul Lee
- College of Nursing, Nursing Policy Research Institute, Yonsei University, Seoul, Korea.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Sgreccia E, Di Pietro ML. The role of responsibility in gynecological oncology. LINACRE QUARTERLY 2004; 70:183-94. [PMID: 15040353 DOI: 10.1080/20508549.2003.11877677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Elio Sgreccia
- Institute of Bioethics, School of Medicine, Catholic University of Sacred Hearth, Rome, Italy
| | | |
Collapse
|
6
|
Abstract
Breast cancer is a major cause of female morbidity and mortality worldwide. In this review, we discuss the hormonal and genetic risk factors associated with breast cancer development and describe the currently available models for predicting an individual woman's risk. We highlight three more sophisticated surrogate markers of life-time oestrogen exposure (plasma oestradiol, mammographic breast density, bone mineral density) and propose that these may be used to improve estimates of a woman's absolute risk.
Collapse
Affiliation(s)
- A Clamp
- Department of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada
| | | | | |
Collapse
|
7
|
Marie Swanson G, Haslam SZ, Azzouz F. Breast cancer among young African-American women: a summary of data and literature and of issues discussed during the Summit Meeting on Breast Cancer Among African American Women, Washington, DC, September 8-10, 2000. Cancer 2003; 97:273-9. [PMID: 12491491 DOI: 10.1002/cncr.11025] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND African-American women younger than age 45 years have a higher risk of incidence and mortality due to breast cancer than other women. The reason for this disparity in risk is not well understood. METHODS This review summarizes the literature on the topic of breast cancer in young women and presents a summary of a discussion on this topic during a national forum on breast cancer among African-American women. RESULTS The occurrence of breast cancer among African-American women younger than the age of 45 years has not been well studied. There is a clear and long-term pattern of higher incidence and mortality and poorer survival in this population subgroup. CONCLUSION Research is needed to understand the reasons for these disparities and to reduce or eliminate them. Studies focused on hormonal factors, genetic factors, diet and obesity, and timely access to state-of-the-art prevention, information, screening, diagnosis, and treatment are likely to produce important new knowledge in this area.
Collapse
Affiliation(s)
- G Marie Swanson
- Mel and Enid Zuckerman Arizona College of Public Health, University of Arizona, Tucson, Arizona 85724, USA.
| | | | | |
Collapse
|
8
|
Hemminki E, Luostarinen T, Pukkala E, Apter D, Hakulinen T. Oral contraceptive use before first birth and risk of breast cancer: a case control study. BMC Womens Health 2002; 2:9. [PMID: 12160467 PMCID: PMC122097 DOI: 10.1186/1472-6874-2-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2002] [Accepted: 08/05/2002] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND: The aim of this study was first, to investigate whether women starting oral contraceptive (OC) use at a young age and before first birth have an increased risk for breast cancer and second, to report difficulties encountered in studying long-term health impacts of medical technologies. METHODS: Breast cancers occurring up until 1997 among 37153 Helsinki students born between 1946 and 1960 were identified by record linkage from the Finnish Cancer Registry; for each cancer case, five age-matched random controls were picked from the same student population. Those who had used the Helsinki Student Health Service (HSHS) at least three times (150 cases and 316 controls) form the final study subjects. Data on OC use and background characteristics were collected from patient records, and data on live births were derived from the population register. Odds ratios (OR) were adjusted for number of births, smoking and sports activity. RESULTS: Compared to the few non-users, OC users had a higher risk of breast cancer: the adjusted OR was 2.1 (95% confidence interval 1.1-4.2). Among OC users, no statistically significant differences in risk of breast cancer were found in regard to starting age or first birth, but small numbers made confidence intervals wide. Even though we had chosen students to be our study group, the population turned out to be unsuitable to answer our research question: most women had started their OC use old (at the age of 20 or later) and there were very few unexposed (almost all had used OC and before their first birth). CONCLUSIONS: Because adoption of the modern pattern of OC use was not common among students, it is unlikely that the impact of early and extended OC use can be studied before 2010, when women born in the 1960s are 40 to 50 years old.
Collapse
Affiliation(s)
- Elina Hemminki
- National Research and Development Center for Welfare and Health, Health Services Research, Helsinki, Finland
| | - Tapio Luostarinen
- Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland
| | - Eero Pukkala
- Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland
| | - Dan Apter
- Finnish Student Health Service and Family Federation of Finland, Helsinki, Finland
| | - Timo Hakulinen
- Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland
- Department of Public Health, University of Helsinki, Finland
| |
Collapse
|
9
|
Tryggvadóttir L, Tulinius H, Eyfjord JE, Sigurvinsson T. Breast cancer risk factors and age at diagnosis: an Icelandic cohort study. Int J Cancer 2002; 98:604-8. [PMID: 11920622 DOI: 10.1002/ijc.10217] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
An increasing number of studies indicates that the strength and even direction of association between breast cancer and established risk factors differ according to the woman's age when she develops the disease. This was studied in the setting of a population based cancer registry using a databank with information on age at menarche, parity, age at first birth, oral contraceptive (OC) use, lactation, height and weight. From a cohort of 80.219 women attending population-based cervical and breast cancer screening in Iceland, 1120 cases were identified, aged 26-90 years at diagnosis and 10,537 controls, individually matched to the cases on birth year and age when attending. Information given at last visit before diagnosis was used in the analysis, applying conditional logistic regression. Odds ratios and statistical strength of relationships varied according to age at diagnosis for age at first birth, number of births, duration of lactation, height and weight. The decreased risk associated with young age at first birth and increasing duration of breast feeding became less pronounced with advancing age at diagnosis. A reduced risk associated with an increasing number of births was not detected in women diagnosed under the age of 40. An increased risk associated with giving first birth after 30 years of age was mainly detected in women who had only given 1 birth and were diagnosed under the age of 40 (OR = 7.06 95% CI = 2.16-23.01). A positive association with height and especially with weight was confined to women diagnosed after the age of 55. The results confirm that age at diagnosis should be taken into account when studying the effects of breast cancer risk factors.
Collapse
|
10
|
Abstract
Most up-to-date information on oral contraceptives (OCs) and breast cancer risk comes from a collaborative re-analysis of individual data on 53297 cases and 100239 controls. It is now established that there is a moderately increased breast cancer risk among current OC users, which tends to level off in the few years after stopping use. With regard to cervical cancer, OC use has been found to be associated with increased risk in human papilloma virus-positive women. With reference to the well known protective effects of OCs against endometrial carcinogenesis, additional information has suggested a consistent protection across types of OCs used. Further data on ovarian cancer confirm that the protection of OCs is long lasting, and may well be observed 15 to 20 years after stopping use. Several studies have suggested an inverse relationship between use of OCs and risk of colorectal cancer, and in a meta-analysis of published data the pooled relative risk of colorectal cancer for DC ever-use was 0.82 (95% confidence interval 0.74 to 0.97). There was no association with duration of use. The increased risk for hepatocellular carcinoma in the absence of hepatitis B viruses is the only established evidence of a direct association between OC use and cancer risk, which led an International Agency for Research on Cancer Working Group to classify OCs as carcinogenic to humans in 1998.
Collapse
Affiliation(s)
- C La Vecchia
- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
| | | | | | | |
Collapse
|
11
|
Affiliation(s)
- M Clemons
- Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
| | | |
Collapse
|
12
|
Bukvic N, Susca F, Bukvic D, Fanelli M, Guanti G. 17-alpha-ethinylestradiol and norgestrel in combination induce micronucleus increases and aneuploidy in human lymphocyte and fibroblast cultures. TERATOGENESIS, CARCINOGENESIS, AND MUTAGENESIS 2000; 20:147-59. [PMID: 10820425 DOI: 10.1002/(sici)1520-6866(2000)20:3<147::aid-tcm6>3.0.co;2-t] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Oral contraceptives are highly efficient and easily administered drugs; however, it must not be forgotten that they are composed of chemical substances which can be classified as potential carcinogens. Testing of a substance for genotoxicity represents a reliable approach both to evaluate the genetic hazard and to obtain information on its possible tumorigenic (cancerogenic) properties. The present study was undertaken to evaluate through carefully planned and controlled investigations the in vitro cytogenetic effects of oral contraceptives (ethynilestradiol and norgestrel mixed in the proportion 1:5) using three different concentrations, with two different durations of treatment (48 and 72 h), on two types of human cells (lymphocytes and fibroblasts) and a series of short-term test procedures: sister chromatid exchange (SCE), micronucleus test (MN), and chromosome aberrations (CA). In addition, the FISH procedure and in vitro anaphase and metaphase preparation analyses were performed. In contrast to CA and SCE frequencies, the frequency of MN in treated blood lymphocytes showed higher values by comparison with the controls, although the difference was statistically significant only for the lowest concentration (P = 0. 016). When using pancentromeric alphoid probes, the FISH procedure gave positive signals in more than 85% of micronuclei, clearly indicating that MN may contain whole chromosomes rather than acentric fragments. Unlike the lymphocytes, the fibroblasts showed dose-dependent effects, although those treated with the highest hormone concentrations showed an increased number of highly damaged cells (cytoplasmatic vacuolization, nuclear fragmentation, etc.), a decreased number of anaphase cells, a large number of which were abnormal, and a reduction of mitotic index. In conclusion, our data confirm that hormones do not induce structural chromosome aberrations in lymphocytes and indicate that ethynilestradiol and norgestrel have an aneugenic effect on fibroblast and lymphocyte cultures; FISH analysis on micronuclei from lymphocyte cultures and anaphase preparations from fibroblast cultures support this hypothesis. Teratogenesis Carcinog. Mutagen. 20:147-159, 2000.
Collapse
MESH Headings
- Aneuploidy
- Cells, Cultured/drug effects
- Cells, Cultured/ultrastructure
- Chromosome Aberrations
- Contraceptives, Oral, Combined/pharmacology
- Contraceptives, Oral, Combined/toxicity
- Contraceptives, Oral, Hormonal/pharmacology
- Contraceptives, Oral, Hormonal/toxicity
- DNA Damage
- Dose-Response Relationship, Drug
- Ethinyl Estradiol/administration & dosage
- Ethinyl Estradiol/pharmacology
- Ethinyl Estradiol/toxicity
- Fibroblasts/drug effects
- Fibroblasts/ultrastructure
- Humans
- In Situ Hybridization, Fluorescence
- Lymphocytes/drug effects
- Lymphocytes/ultrastructure
- Micronucleus Tests
- Norgestrel/administration & dosage
- Norgestrel/pharmacology
- Norgestrel/toxicity
- Safety
- Sister Chromatid Exchange/drug effects
Collapse
Affiliation(s)
- N Bukvic
- DIMIMP-Sezione di Genetica Medica-Università degli Studi, Bari, Italy
| | | | | | | | | |
Collapse
|
13
|
|
14
|
|
15
|
Tömasson H. Oral contraceptive (OC) use and risk of breast cancer. Br J Cancer 1997; 76:416-8. [PMID: 9252213 PMCID: PMC2224067 DOI: 10.1038/bjc.1997.400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
|